thank us. joining you and morning Good for
provide quarterly by revenue and and results. additional our opening I business update before a opening followed guidance XXXX For call, regarding our today's Q&A. to Kevin, with Starting will provide will performance who comments details financial the call
to patients pleased quarter the to and our continue clinical realize are benefits We report strong Aquablation another significant customers of therapy. where
commercial clinical private Robotic combination of continued real We team our adoption of coverage, field-based in was primarily quarter install from the AquaBeam to quarter representing of base utilization outcomes, and positive to growth patient strong outstanding the quarter an first for million, the an driven first Growth XXXX. surgeon and believe XX% and revenue drive XXXX of data, increased expanded expanded $XX.X was increased Total by of interest long-term world patient System. payer compared volume. the
to give the our move touch we care. degree reflect standard laying the these several that to factors are guidance, which to we achieve foundation term, later. full on As believe BPH and will increased we positive financial high is business a competence the XXXX, underlying fundamentals us become year there surgical Longer believe of Kevin of
a on coverage. with we medically will payer X, with announced positive to commercial include United the United's surgery will United April, interventions one XXXX. men covered policy Starting accessibility of suffering updated the our June that for recent therapy its necessary. early Aquablation in lives, In coverage policy largest into This greatly and payers effect as policy go Aquablation updated Healthcare of Being BPH. XX improve million States, approximately from prostate for
we Michigan, be early Cross May Blue the payer obtained Blue will state in of also Cross of Shield from March, X. Additionally, Shield which a and coverage in policy X.X million Blue of covers is approximately Blue lives. positive Michigan effective largest Michigan, the
Aquablation we therapy. XX% of additions estimate in the our have access of of Cross the U.S. men Blue now Michigan, Shield United With and roughly to Blue Healthcare
increased payer surgical of equipment the obvious a lowering short-term market. the a The technology is as There barriers commercial take and is long-term hospitals. is value capital the both of we The long-term to which increasing utilization, benefit and short-term benefit penetrate increased our to benefit proposition time will of coverage. sell
conference weekend, our Urological the at Chicago, clinical releasing Association study data. will in American to updates. be WATER This II Turning five-year we
also five-year to XXX change FDA milliliters. primary remain objective endpoints, prospective IPSS as results measured from five with efficacy in study with previously reminder, II to an data the safety and size Qmax by ranging years. change The criterion reported in were both with was a for and consistent performance no consistent in large results. at WATER efficacy The safety As a prostate XX
of therapy for abstract safety WATER efficacy comparing the XX and at study will TURP Additionally, presented treatment versus be milliliter of prostates. AUA Aquablation five-year XX to
reminder, prospective of efficacy Aquablation pivotal milliliters. to safety study double-blind, FDA only are randomized, As TURP XX a comparing prostate the five-year the multicenter data XX therapy our for from WATER and to ranging
five back or due proves TURP. represented was by irreversible surgical abstract durability this an therapy's compared retreatment, to requiring to better patients rate. which retreatment Aquablation This X% Aquablation complication superior therapy that This In measured superior abstract, by symptom Xx to safety and low med than relief. going exhibited is approximate annual at is years
body advantages clinical clinical studies, therapy. be developed a two modalities studies, and and significant XXX clinical backdrop replace supporting will sizes and benefits the across includes now believe five-year choosing the customers differentiator surgical a all continue have our for of which significant Aquablation FDA BPH this all with shapes. of therapy durability prostate We when peer-reviewed over we to to Aquablation company, and historical evidence, a other growing As seven publications,
touch to our revenue commercial $X.X want Systems I the AquaBeam which QX saw U.S. first In million, at Next, was end range. quarter, guidance low organization. the total system our we Robotic XX of on generating of
our earnings February, QX impact timing we quarter-to-quarter. in sales play pipeline provided a our QX in in range to investors order capital give sales call can and insight late During of into the
guidance, be XX% last XXXX in two to the expectation XXXX. guidance issued since of system sales still full our we has in of and XXXX the first sales we year system half expect not and Our changed months around approximately
in of capital terms our meaningfully, greenfield pipeline, of placement the opportunities number territories. grow which In by to driven continue has new been of addition robot reps the
catalysts positive for recent confidence year payment XXXX of more in our full full pass-through the guidance. all transitional and the strengthens associated extension announcement of our Healthcare United with the Additionally,
of of capital which capital about our we entered specifically XXXX. Speaking XX XX approximately late sales added the first quarter personnel, sales were reps, in XXXX QX with
Thus, we the to XXXX reps the contributing they start do pipelines. quarter productivity respective the a will system not is capital sales half reps second in approximately fourth to be months, of XXXX. expect out As capital meaningfully building the six for of for their U.S. reminder, until responsible curve added as
are what how productivity in are rates. overall of to we and progress, close Our informed ramp the XXXX pipeline, reps customers seeing guidance continues new us, telling capital what by our be opportunities
of therapy around which All continues to as indicators awareness in momentum objectives. have Aquablation us grow, our these commercial maintained confidence gives positive achieving XXXX
at handpieces an to pricing This as surgeon want securing will I allow IDN secures IDN us, and contracted more it our operate team touch milestone our system is national we these manner We nationwide a hospitals. sold largest for to significant with a progress placement Aquablation signed with Next, in on champion sales expedited predictable with hospital as that recently sales network. the contract partner for and contracts.
strategic our As end IDNs having the QX contract we by majority the of in the anticipate stated XXXX. on large U.S. of under earnings call,
the high-volume While increased having there we to as the are the X,XXX network. greater contracts approximately and of the XX% provide in importance Thus hospital the hospitals pipeline. XX hospitals. to strategic many estimate market, market for in IDNs of BPH or of the equal BPH and total XXX U.S. penetrate visibility meaningful XX% our networks When our account strategic XX in hospitals States, we than these United ability categorize analyzing is IDNs
and Turning to activity. surgeon utilization
of pleased handpiece where extremely compared XXXX. consumable XXX% QX increased with revenue first U.S. and to approximately utilization We quarter are the
growth, emerged driver While monthly trends be active utilization extremely have key the are two that there that us. last surgeon continues to over XX positive are of the for primary months
quarter. define The current active in case We retention and who previous the first any is surgeon retention. as surgeon both active surgeon a performs
of XXXX, quarter first were than surgeon the In XX%. greater retention rates
retention our to and As Aquablation therapy's benefit safely surgeons. focus greatly a high size on commercial this We shape as and ability level and effectively. team ease all use prostate believe can surgeon company, treat we from training of of the this demonstrates
emerging second hospital utilization low-volume among The BPH accounts. is trend
see which for however, While surgeries. starting nice we focused hospitals XXX the from accounts, base. centers, we performed are current of also our are historically not roughly primarily install many high-volume surgery are BPH have hospitals, adoption of these accounts XX% low-volume large Many on BPH to
Aquablation While accounts has points early referred would do likely to to definitive otherwise patients low-volume allowed treat believe therapy have out. expansion, regarding they market make too we
along valuable hospitals believe interactions, Given with commercial team. the positive we awareness momentum very our low-volume of Aquablation for therapy, expanded are target in peer-to-peer
respect removal of activities. Innovation care the with of or therapy is of has the NICE BPH to for the February, the life. received tissue from offers therapy experts a NICE Institute for recognized to increased effective such additional early technology quality international standard to ability Briefing MedTech Aquablation Clinical In in Care the Kingdom. Excellence market patients. United as innovative benefits, BPH Lastly, is Health said preserve development National Aquablation that and prostate compared for for
and will prostate prostates. holmium review technology of the with has potential the enucleation the to TURP stated experts for Clinical that replace associated the laser larger also challenge
is for UK While small, our the of future. the guidance reimbursement from at the an levels to Aquablation currently company therapy that attractive be updated UK similar given market NICE believe U.S., presence we our could for in this the and in establish
urologists our the and learn we surgeon of who about also therapy. we international customers more enthusiastic strong feedback March, At European European Urology of received to other Aquablation were attended positive Association In data them Milan. conference, in driving and clinical the hundreds met from about with
finalize we achieve of In ability our than higher confidence growth about have at degree Every feel today in metric I better point and direction right just track IDNs year. is the our continue the moving and strategic business to and to any our national sales summary, this a plan. long-term summarize grow continues with expect to in contract nicely. the to catalyst, signed We largest IDN and a pipeline other funnel with to throughout large our contracts
positive and and hires to greenfield progressing United coverage through we Aquablation access recent XXXX. they the full metric. our as our have continues to build respective in providing Healthcare sales therapy patient lastly, the transitional full Utilization our approximately a received guidance this U.S. rep nicely We from our payment exceed XX% have pass-through very And territories. expectations, around year increased are policy
truly believe Aquablation momentum, this Given positive treatment BPH. therapy the of revolutionize will we
over Kevin. I that, the will turn call With to
